Articles publicats

Cerca col·leccions:

Ordena'ls per:	Mostrar els resultats:	Format de visualizació:

Articles publicats	1 registres trobats	La cerca s'ha fet en 0.02 segons.

8 p, 976.6 KB

Efficacy and safety of ozanimod in multiple sclerosis : Dose-blinded extension of a randomized phase II study / Cohen, Jeffrey A. (Mellen Center for MS Treatment and Research, Cleveland Clin) ; Comi, Giancarlo (Vita-Salute San Raffaele University) ; Arnold, Douglas Lorne (McGill University, Montreal) ; Bar-Or, Amit (University of Pennsylvania. Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology) ; Selmaj, Krzysztof W. (Center for Neurology, Łódź, Poland) ; Steinman, Lawrence (Stanford University Medical Center) ; Havrdová, Eva K. (Charles University. Department of Neurology and Center for Clinical Neuroscience) ; Cree, Bruce A. C. (University of California. UCSF Weill Institute for Neurosciences) ; Montalbán, Xavier (Universitat Autònoma de Barcelona. Departament de Medicina) ; Hartung, Hans-Peter (Heinrich Heine University. Department of Neurology) ; Huang, Vivian (Celgene Corporation, San Diego, CA) ; Frohna, Paul (Celgene Corporation, San Diego, CA) ; Skolnick, Brett E. (Celgene Corporation, San Diego, CA) ; Kappos, Ludwig (University Hospital Basel (Basilea, Suïssa))
Ozanimod, an oral immunomodulator, selectively targets sphingosine 1-phosphate receptors 1 and 5. Evaluate efficacy, safety, and tolerability of ozanimod in relapsing multiple sclerosis. In the RADIANCE Part A phase II study (NCT01628393), participants with relapsing multiple sclerosis were randomized (1:1:1) to once-daily ozanimod hydrochloride (0. [...]
2018 - DOI (Digital Object Identifier)

10.1177/1352458518789884
Multiple sclerosis, Vol. 25 (july 2018) , p. 1255-1262

Registre complet -

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.